NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $9.66 -0.35 (-3.48%) Closing price 03:59 PM EasternExtended Trading$9.66 +0.00 (+0.03%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Corvus Pharmaceuticals Stock (NASDAQ:CRVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corvus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.56▼$10.0450-Day Range$9.38▼$13.4452-Week Range$6.39▼$26.95Volume927,517 shsAverage Volume1.82 million shsMarket Capitalization$815.02 millionP/E RatioN/ADividend YieldN/APrice Target$32.83Consensus RatingModerate Buy Company Overview Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis. Corvus was founded in 2014 and is led by co-founder Richard A. Miller, who serves as president and chief executive officer. The company’s development activities are focused on advancing its drug candidates through clinical research.AI Generated. May Contain Errors. Read More Corvus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreCRVS MarketRank™: 2.776481888035 of 5 starsCorvus Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 402nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCorvus Pharmaceuticals has a consensus price target of $32.83, representing about 239.8% upside from its current price of $9.66.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -13.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -13.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.29% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 18.85, which indicates bearish sentiment.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 1.16%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.05 News SentimentCorvus Pharmaceuticals has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Corvus Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest3 people have searched for CRVS on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.4 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $50,478.00 in company stock, which represents 0.0062% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,478.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.70% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRVS Stock News HeadlinesCorvus Pharmaceuticals, Inc. (CRVS) - What Are Researchers Thinking About This Stock?November 17 at 2:15 AM | americanbankingnews.comInsider Buying: Corvus Pharmaceuticals (NASDAQ:CRVS) Insider Acquires 1,003 Shares of StockNovember 15, 2026 | insidertrades.comPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 20 at 1:00 AM | Base Camp Trading (Ad)FY2026 Earnings Estimate for CRVS Issued By HC WainwrightNovember 15, 2026 | americanbankingnews.comCorvus Pharmaceuticals Earnings Call Signals 2027 MilestonesNovember 15, 2026 | tipranks.comAnalysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), Achieve Life Sciences (QUIT)November 13, 2026 | theglobeandmail.comCorvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real ProductNovember 10, 2026 | seekingalpha.comCorvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027November 9, 2026 | seekingalpha.comSee More Headlines CRVS Stock Analysis - Frequently Asked Questions How have CRVS shares performed this year? Corvus Pharmaceuticals' stock was trading at $7.70 at the beginning of 2026. Since then, CRVS stock has increased by 25.5% and is now trading at $9.6620. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03. Read the conference call transcript. When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' top institutional shareholders include State Street Corp (3.95%), Fisher Asset Management LLC (1.24%), Goldman Sachs Group Inc. (0.77%) and Blue Owl Capital Holdings LP (0.43%). Insiders that own company stock include Peter A Thompson, Richard A Md Miller, William Benton Jones, David Scott Moore and Jeffrey Arcara. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Palantir Technologies (PLTR), Tesla (TSLA) and Delta Air Lines (DAL). Company Calendar Last Earnings11/05/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CRVS's financial health is in the Yellow zone, according to TradeSmith. CRVS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRVS CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees37Year Founded2014Price Target and Rating Average Price Target for Corvus Pharmaceuticals$32.83 High Price Target$42.00 Low Price Target$27.00 Potential Upside/Downside+239.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.28 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.98% Return on Assets-32.67% Debt Debt-to-Equity RatioN/A Current Ratio13.38 Quick Ratio13.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.12 per share Price / Cash Flow80.39 Book Value$2.47 per share Price / Book3.91Miscellaneous Outstanding Shares84,353,000Free Float67,735,000Market Cap$815.02 million OptionableOptionable Beta1.57 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CRVS) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.